Jolie's announcement of her mastectomy attracted widespread publicity and discussion on BRCA mutations and genetic testing. Her decision was met with praise from various public figures, while health campaigners welcomed her raising awareness of the options available to at-risk women. Dubbed "The Angelina Effect" by a "Time" cover story, Jolie's influence led to a "global and long-lasting" increase in BRCA gene testing: the number of referrals tripled in Australia and doubled in the UK, parts of Canada, and India, as well as significantly increased in other European countries and the U.S. Researchers in Canada and the UK found that despite the large increase, the percentage of mutation carriers remained the same, meaning Jolie's message had reached those most at risk. In her first op-ed, Jolie had advocated wider accessibility of BRCA gene testing and acknowledged the high costs, which were greatly reduced after the U.S. Supreme Court, in a June 2013 ruling, invalidated BRCA gene patents held by Myriad Genetics.